Kansas DURB Covers Gene Therapies for Sickle Cell Disease
This month, Sick Cells sat down with Kevin Wake to hear about the first Drug Utilization Review Board (DURB) meeting in Kansas to review the newly approved gene therapies, Casgevy (Vertex) and Lyfgenia (bluebird bio) for the treatment of Sickle Cell Disease.